David A. Siegel Pyxis Oncology, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 14,100 shares of PYXS stock, worth $51,747. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,100
Previous 15,600
9.62%
Holding current value
$51,747
Previous $66,000
30.3%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PYXS
# of Institutions
86Shares Held
28.5MCall Options Held
134KPut Options Held
5K-
Deep Track Capital, LP Greenwich, CT4.18MShares$15.4 Million0.45% of portfolio
-
Laurion Capital Management LP New York, NY3.86MShares$14.2 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$10.2 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.56MShares$9.41 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$7.56 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $129M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...